|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 血管紧张素转换酶抑制剂和血管紧张素受体拮抗剂的使用与2019冠状病毒疾病检测阳性之间的关系显示文摘血管紧张素转换酶抑制剂(angiotensin-converting enzyme inhibitor,ACEI)和血管紧张素受体拮抗剂(angiotensin receptor blocker,ARB)在2019新型冠状病毒疾病(coronavirus disease 2019,COVID-19)全球大流行背景下的作用备受争议。此类药物是治疗一些慢性病的必须药物,有建议停止使用这些药物. | Mehta N KalraA Nowacki AS Anjewierden S Han Z Bhat p Rubio AEC Jacob M Procop GW Harrington S Milinovich A Svensson LG Jehi L Young JB Chung MK 周卫(译) 叶鹏(校) | 2020 | 中华高血压杂志2020，28，5： | 9 |
| 2 | RTOG 0211:a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients显示文摘PURPOSE: To determine the safety and efficacy of gefitinib,an epidermal growth factor receptor(EGFR) tyrosine kinase inhibitor,in combination with radiation for newly diagnosed glioblastoma(GBM) patients.METHODS AND MATERIALS: Between March 21,2002,and May 3,2004,Radiation Therapy Oncology Group(RTOG) 0211 enrolled 31 and 147GBM patients in the phase 1 and 2 arms,respectively.Treatment consisted of daily oral gefinitnib started at the time of conventional cranial radiation therapy(RT) and continued post RT for 18 months or until progression.Tissue microarrays from 68 cases were analyzed for EGFR expression.RESULTS: The maximum tolerated dose(MTD) of gefitinib was determined to be 500 mg in patients on non-enzyme-inducing anticonvulsant drugs(non-EIAEDs).All patients in the phase 2 component were treated at a gefitinib dose of 500 mg;patients receiving EIADSs could be escalated to 750 mg.The most common side effects of gefitinib in combination with radiation were dermatologic and gastrointestinal.Median survival was 11.5 months for patients treated per protocol.There was no overall survival benefit for patients treated with gefitinib + RT when compared with a historical cohort of patients treated with RT alone,matched by RTOG recursive partitioning analysis(RPA) class distribution.Younger age was significantly associated with better outcome.Per protocol stratification,EGFR expression was not found to be of prognostic value for gefitinib + RT-treated patients.CONCLUSIONS: The addition of gefitinib to RT is well tolerated.Median survival of RTOG 0211 patients treated with RT with concurrent and adjuvant gefitinib was similar to that in a historical control cohort treated with radiation alone. | Chakravarti A Wang M Robins HI Lautenschlaeger T Curran WJ Brachman DG Schultz CJ Choucair A Dolled-Filhart M Christiansen J Gustavson M Molinaro A Mischel P Dicker AP Bredel M Mehta M | 2013 | 中国神经肿瘤杂志2013，11，1： | 8 |
| 3 | Importance of fatigue and its measurement in chronic liver disease显示文摘The mechanisms of fatigue in the group of people with non-alcoholic fatty liver disease and non-alcoholic steatohepatitis are protean. The liver is central in the pathogenesis of fatigue because it uniquely regulates much of the storage, release and production of substrate for energy generation. It is exquisitely sensitive to the feedback controlling the uptake and release of these energy generation substrates. Metabolic contributors to fatigue, beginning with the uptake of substrate from the gut, the passage through the portal system to hepatic storage and release of energy to target organs (muscle and brain) are central to understanding fatigue in patients with chronic liver disease. Inflammation either causing or resulting from chronic liver disease contributes to fatigue, although inflammation has not been demonstrated to be causal. It is this unique combination of factors, the nexus of metabolic abnormality and the inflammatory burden of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis that creates pathways to different types of fatigue. Many use the terms central and peripheral fatigue. Central fatigue is characterized by a lack of self-motivation and can manifest both in physical and mental activities. Peripheral fatigue is classically manifested by neuromuscular dysfunction and muscle weakness. Therefore, the distinction is often seen as a difference between intention (central fatigue) versus ability (peripheral fatigue). New approaches to measuring fatigue include the use of objective measures as well as patient reported outcomes. These measures have improved the precision with which we are able to describe fatigue. The measures of fatigue severity and its impact on usual daily routines in this population have also been improved, and they are more generally accepted as reliable and sensitive. Several approaches to evaluating fatigue and developing endpoints for treatment have relied of biosignatures associated with fatigue. These have been used singly or in combination and include: physical performance measures, cognitive performance measures, mood/behavioral measures, brain imaging and serological measures. Treatment with non-pharmacological agents have been shown to be effective in symptom reduction, whereas pharmacological agents have not been shown effective. | Lynn H Gerber Ali A Weinstein Rohini Mehta Zobair M Younossi | 2019 | World Journal of Gastroenterology2019，25，28： | 7 |
| 4 | Constrictive pericarditis显示文摘 | Mehta A Mehta M Jain AC | 1999 | Clin Cardiol1999，22，5： | 1 |
| 5 | Identification of Posttrans lationally Modified 18-Kilodalton Protein from Rice as Eukaryotic Translation Initiation Factor 5A显示文摘 | Mehta A M Saftner R A Mehta R A | 1994 | Plant Physiol1994，106，4： | 1 |
| 6 | Excitotoxicity: bridge tovarious triggers in neurodegenerative disorders 显示文摘 | Mehta A Prabhakar M Kumar P | 2013 | Eur JPharmacol2013，698，13： | 1 |
| 7 | Cardiac arrhythrnias in pregnancy: Clinical and therapeutic considerations显示文摘 | Gowda R M Khan I A Mehta N J | 2003 | Int J Cardiol2003，88，： | 1 |
| 8 | Some trigonometric identities encountered by McCoy and Orrick显示文摘 | Gervois A Mehta M L | 1995 | Journal of Mathematical Physics1995，36，： | 1 |
| 9 | 查看详情显示文摘 | Haynam C A Wegner P J Auerbach J M Bowers M W Dixit S N Erbert G V Heestand G M Henesian M A Hermann M R Jancaitis K S Manes K R Marshall C D Mehta N C Menapace J Moses E Murray J R Nostrand M C Orth C D Patterson R SacksR A Shaw M J Spaeth M Sutton S B W | | 0，，： | 1 |
| 10 | Genetic variation of antigen processing machinery components and association with cerivical carcinoma 显示文摘 | Mehta A M Jordanova E S Van Wezel T | 2007 | Genes Chromosomes Cancer2007，46，： | 1 |
| 11 | Preoperative hepatic vascular evaluation with CT and MR angiography:implications for surgery显示文摘 | Sahani D Mehta A Blake M | 2004 | Radiographics2004，24，5： | 1 |
| 12 | Heavy metal induced oxidative stress & its possible reversal by chelation therapy显示文摘 | FLORA S J MFITAL M MEHTA A | 2008 | The Indian J Mocl RES2008，128，4： | 1 |
| 13 | Effect of compressed CO2 on crystallization and melting behavior of isotactic polyproplene显示文摘 | Varma-Nair M Handa P Y Mehta A K | 2003 | ThermochimicaActa2003，396，： | 1 |
| 14 | Initial presentation of acute transverse myelitis in systemic lupus erythematosus : demographics, diagnosis, man- agement and comparison to idiopathic cases显示文摘 | Schulz S W Shenin M Mehta A Kebede A Fluerant M Derk CT | 2012 | Rheumatolo- gy International2012，32，9： | 1 |
| 15 | Behavior problems in nephrotie syndrome 显示文摘 | MEHTA M BAGGA A PANDE P | 1995 | Indian Pediatr1995，32，12： | 1 |
| 16 | Air injection in heavy oil reservoirs--a process whose time has come (again)显示文摘 | URSENBACH M G MOORE R G MEHTA S A | 2010 | Journal of Canadian Petroleum Technology2010，49，1： | 1 |
| 17 | Supplementation with RD antigens enhances the protective efficacy of BCG in tuberculous mice显示文摘 | Kalra M Grover A Mehta N | 2007 | Clin Immunol2007，125，2： | 1 |
| 18 | Behavior problems in nephrotic syndrome 显示文摘 | Mehta M Bagga A Pande P | 1995 | Indian Pediatr1995，32，12： | 1 |
| 19 | Heavy metal induced oxidative stress & its possible reversal by chelation therapy显示文摘 | FLORA S J MITAL M MEHTA A | 2008 | Indian J Med Res2008，128，4： | 1 |
| 20 | Simple estimation of prevalence of Hortonian flow in New York City Watershed显示文摘 | Walter M T V K Mehta A M Marrone J | 2003 | Journal of Hydrology Engineering2003，，8： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员